Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pivot Pharmaceuticals Exploring Potential Cannabis Partnership

By Mike Botta | December 28, 2017

Pivot enters into standstill agreement.

Pivot Pharmaceuticals Inc. has entered into a 45-day “standstill period” with an unnamed Toronto Stock Exchange-listed company to explore a “potential transaction” on health-related cannabis that may include a co-research and development program, a product launch and/or commercialization agreement, or some other form of partnership.

Dr. Patrick Frankham, Pivot’s CEO, said in a statement that the company is working to secure a partner to monetize its patented technologies and commercialize its products in preparation for the legalization of cannabis in Canada and areas of the U.S. and EU.

During the past few months Pivot garnered interest from established companies in the nutraceutical and cannabis industries, Frankham added. He did not mention the names of any companies or potential partners.

The standstill period will end on February 6, 2018.

“During this time Pivot will not, directly or indirectly, conduct or enter negotiations or engage in any other discussions or communications with any third party regarding a potential transaction, any sale of all or substantially all of the assets of Pivot, or any merger, amalgamation, plan of arrangement or other business combination involving Pivot,” according to a company statement.

Pivot’s wholly owned medical cannabis products division, Pivot Green Stream Health Solutions Inc., conducts research, development, and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals.

Its initial product development candidates include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care.

(Source: Pivot Pharmaceuticals Inc.)

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards